Cytochrome P450 2D6 (CYP2D6) Genotyping
The cytochrome P450 (CYP450) enzymes catalyze the oxidation of many drugs and chemicals in our body. CYP450 is a large enzyme family mostly found in the liver. Since these enzymes have more than 50 isoenzymes (variations), their activity may vary from person to person. Individual differences of cytochrome P450 activity can result in variation from total absence or decreased metabolism of certain drugs to ultrafast or increased metabolism of drugs. This can lead to adverse drug reactions or a lack of therapeutic effect under standard therapy conditions.
CYP2D6 is gene 6 within the D subfamily, in the 2 family of CYP450. It metabolizes 25% of all prescribed drugs, such as codeine, tricyclic antidepressants (e.g., nortriptyline), SSRI fluvoxamine, SSNRI venlafaxine, classical antipsychotics (e.g., haloperidol), and beta-blockers. Four distinct phenotypes (observable variations) are found with regard to the enzyme's activity in the human body: normal metabolizers (NM), poor metabolizers (PM), intermediate metabolizers (IM), and ultra rapid metabolizers (URM).
CYP2D6 *1 and *2 are normal metabolizers, *3 through *6 are poor metabolizers and are the four most common alleles which account for approximately 95% of the mutations found in the Caucasian population. Intermediate metabolizers contain one functional and one mutant CYP2D6 alleles. Varying allele groups such as CYP2D6 *6 through *8, *11 through *16, *19 , *20 and *38 are known to lack enzyme activity for drugs such as dextromethorphan, sparteine, and bufarulol. This is a particularly rare combination of these alleles. Specific variants in this gene also influence the metabolism of the breast cancer drug tamoxifen in postmenopausal women. Genetic polymorphisms of CYP2D6 could be used to predict the altered enzyme activity and address the potential effects of metabolized drugs. The metabolism of drugs is also influenced by race, ethnicity, diet, and medications. All factors should be considered prior to initiating new therapy.
- Determining therapeutic strategy for therapeutics that are metabolized by the CYP450 2D6 gene product (antidepressant and other metabolized drugs)
- Monitor and manage antidepressant drug therapy
CYP2D6 \*1/\*1 (Normal Metabolizer)
Blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Clin Lab. 2011;57(11-12):887-93. [PMID: 22239018]
- AAPS Pharm Sci. 2000; 2:E33. [PMID: 11741249]
- Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104. [PMID: 15779673]
- Am J Hum Genet. 1997 Feb;60(2):284-95. [PMID: 9012401]
- Biol Chem. 2005 Aug 5;280(31):28324-31. [PMID: 15937338]
- Pharmacogenet Genomics. 2005 Sep;15(9):625-31. [PMID: 16041241]
- Clin Pharmacokinet. 2006;45(1):13-31. [PMID: 16430309]